Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This study aimed to compare the outcomes of two distinct patient populations treated within two neighboring UK cancer centers (A and B) for advanced epithelial ovarian cancer (EOC).
A retrospective analysis of all new stages 3 and 4 EOC patients treated between January 2013 and December 2014 was performed. The Mayo Clinic surgical complexity score (SCS) was applied. Cox regression analysis identified the impact of treatment methods on survival.
The study identified 249 patients (127 at center A and 122 in centre B) without significant differences in International Federation of Gynecology and Obstetrics (FIGO) stage (FIGO 4, 29.7% at centers A and B), Eastern Cooperative Oncology Group (ECOG) performance status (ECOG < 2, 89.9% at centers A and B), or histology (serous type in 84.1% at centers A and B). The patients at center A were more likely to undergo surgery (87% vs 59.8%; p < 0.001). The types of chemotherapy and the patients receiving palliative treatment alone were equivalent between the two centers (3.6%). The median SCS was significantly higher at center A (9 vs 2; p < 0.001) with greater tumor burden (9 vs 6 abdominal fields involved; p < 0.001), longer median operation times (285 vs 155 min; p < 0.001), and longer hospital stays (9 vs 6 days; p < 0.001), but surgical morbidity and mortality were equivalent. The independent predictors of reduced overall survival (OS) were non-serous histology (hazard ratio [HR], 1.6; 95% confidence interval [CI] 1.04–2.61), ECOG higher than 2 (HR, 1.9; 95% CI 1.15–3.13), and palliation alone (HR, 3.43; 95% CI 1.51–7.81). Cytoreduction, of any timing, had an independent protective impact on OS compared with chemotherapy alone (HR, 0.31 for interval surgery and 0.39 for primary surgery), even after adjustment for other prognostic factors.
Incorporating surgery into the initial EOC management, even for those patients with a greater tumor burden and more disseminated disease, may require more complex procedures and more resources in terms of theater time and hospital stay, but seems to be associated with a significant prolongation of the patients overall survival compared with chemotherapy alone.
Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Am J Obstet Gynecol. 2006;107:77–85. CrossRef
Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33:937–43. CrossRef
Fotopoulou C, Sehouli J, Aletti G, et al. Value of neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer: a European perspective. J Clin Oncol. 2017;35:587–90. CrossRef
Tseng JH, Cowan RA, Zhou Q, et al. Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival? Gynecol Oncol. 2018;151:24–31. CrossRef
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59. CrossRef
Fotopoulou C, Jones BP, Savvatis K, et al. Maximal-effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Arch Gynecol Obstet. 2016;294:607–14. CrossRef
Gómez-Hidalgo NR, Martinez-Cannon BA, Nick AM, et al. Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care. Gynecol Oncol. 2015;137:553–8. CrossRef
Aletti GD, Dowdy SC, Gostout BS, et al. Quality improvement in the surgical approach to advanced ovarian cancer: the Mayo Clinic experience. J Am Coll Surg. 2009;208:614–20. CrossRef
Sundar S, Kumar S, Long J, et.al. Patient-reported outcomes after surgery in advanced ovarian cancer: initial results from the international, prospective, multicentre SOCQER 2 study. In: 17th Biennial meeting of the international Gynecologic Cancer Society Kyoto, Japan, 14–16 Sept 2018 (abstract 034). https://dx.doi.org/10.1136/00009577-201809002-00001.
Phillips A, Balega J, Nevin J, Singh K, Elattar A, Kehoe S, et al. Reporting “denominator” data is essential for benchmarking and quality standards in ovarian cancer. Gynecol Oncol. 2017;146:94–100. CrossRef
Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26:1354–63. CrossRef
Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C, Werner L, et al. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99:424–7. CrossRef
Fotopoulou C, Hall M, Cruickshank D. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol. 2017;213:123–39. CrossRef
Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63. CrossRef
Clamp A, McNeish I, Dean A, et al. ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis. Program and abstracts of the European Society for Medical Oncology 2017 Congress, 8–12 Sept 2017, Madrid, Spain (abstract 929O_PR).
Barclay M, Gildea C, Poole J, et al. Factors affecting short-term mortality in women with ovarian, tubal, or primary peritoneal cancer: population-based cohort analysis of English National Cancer Registration Data. Int J Gynecol Cancer. 2016;26:56–65. CrossRef
Thrall M, Gray H, Symons R, Weiss NS, et al. Trends in treatment of advanced epithelial ovarian cancer in the medicare population. Gynecol Oncol. 2011;122:100–6. CrossRef
Shalowitz D, Epstein A, Ko E, et al. 2nd Nonsurgical management of ovarian cancer: prevalence and implications. Gynecol Oncol. 2016;142:30–7. CrossRef
Chiva LM, Mínguez J, Querleu D, et al. European surgical education and training in gynecologic oncology: the impact of an accredited fellowship. Int J Gynecol Cancer. 2017;27:819–25. CrossRef
Barber EL, Rossi EC, Gehrig PA. Surgical readmission and survival in women with ovarian cancer: are short-term quality metrics incentivizing decreased long-term survival? Gynecol Oncol. 2017;147:607–11. CrossRef
Aletti GD, Podratz KC, Moriarty JP, Cliby WA, Long KH. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis. Gynecol Oncol. 2009;112(1):16–21. CrossRef
Clark RM, Rice LW, Del Carmen MG. Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review. Gynecol Oncol. 2018;150:370–7. CrossRef
Wise J. Survey of UK doctors highlights blame culture within the NHS. BMJ. 2018;362:k4001. CrossRef
Soo Hoo S, Marriott N, Houlton A, et al. Patient-reported outcomes after extensive (ultraradical) surgery for ovarian cancer: results from a prospective longitudinal feasibility study. Int J Gynecol Cancer. 2015;25:1599–607. CrossRef
Mahner S, Heitz F, Burges A, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO OVAR OP7). JCO. 2017;35:15(Suppl):TPS5602–TPS5602. CrossRef
- Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome
MD, PhD Marcia Hall
MD, PhD Konstantinos Savvatis
MD Katherine Nixon
MD, PhD Maria Kyrgiou
MD Kuhan Hariharan
MD Malcolm Padwick
MD Owen Owens
MD, PhD Paula Cunnea
MD Jeremy Campbell
MD Alan Farthing
MD Richard Stumpfle
MD Ignacio Vazquez
MD Neale Watson
MD, PhD Jonathan Krell
MD, PhD Hani Gabra
MD, PhD Gordon Rustin
MD, PhD Christina Fotopoulou
- Springer International Publishing
Neu im Fachgebiet Chirurgie
Mail Icon II